SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
- 54
PR Newswire
NEW YORK, Dec. 3, 2024
NEW YORK, Dec. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Arvinas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On November 19, 2024, Arvinas disclosed in a filing with the U.S. Securities and Exchange Commission that Arvinas and its partner, Pfizer, Inc., decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant "from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025."
On this news, Arvinas's stock price fell sharply during intraday trading on November 19, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-arvinas-inc---arvn-302321750.html
SOURCE Pomerantz LLP
PR Newswire's news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.
- "Prosperity Lights Up Macao" Special Program Celebrating the 25th Anniversary of Macao's Return to China
- BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering
- Nutanix Announces Pricing of $750 Million 0.50% Convertible Senior Notes
- HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
- Sinopec Receives ISO's Approval for China's First ISO International Technical Specification for Heavy Oil Development
- Chewy, Inc. Announces Pricing of Offering of Class A Common Stock by Selling Stockholder and Concurrent Repurchase
